hrp0084p3-696 | Diabetes | ESPE2015

Influence of hypoglycemic episodes on attention and behavioural abnormalities in diabetic children

Wurm Michael , Niebuhr Vera , Hallermann Kristiane , Krause Alexandra , van der Werf-Grohmann Natascha , Schwab Karl Otfried

Background: Type 1 diabetes may have an influence on concentration, attention and behaviour. These effects are relevant, as they may affect school performance and later career options for paediatric diabetes patients.Objective and hypotheses: This study examined attention, concentration and behavioural difficulties in diabetic children aged 5–13 years and their association with hypoglycaemic episodes and HbA1c.Method: 48 child...

hrp0084p3-1034 | Growth | ESPE2015

Birth Characteristics Influence the Male to Female Diagnostic Prevalence of Idiopathic GH Deficiency

Camacho-Hubner Cecilia , Lindberg Anders , Arnhold Ivo J P , Ranke Michael B

Background: A greater number of male (M) vs female (F) patients are diagnosed with GH deficiency (GHD). M have larger birth weight (BW), length and head circumference (HC) compared to F; these characteristics could contribute to subtle cephalo-pelvic disproportion and mild head trauma possibly contributing to idiopathic GHD (IGHD) and multiple pituitary hormone deficiencies (MPHD).Objective: To determine birth characteristics including mode of delivery a...

hrp0094fc9.3 | Growth Hormone and IGFs | ESPE2021

Once-weekly somapacitan versus daily growth hormone in growth hormone deficiency: 3 year efficacy and safety results from REAL 3, a randomised controlled phase 2 trial

Savendahl Lars , Battelino Tadej , Rasmussen Michael Hojby , Saenger Paul , Horikawa Reiko ,

Growth hormone (GH) replacement therapy currently requires daily subcutaneous injections. Somapacitan is a long-acting GH-derivative in development for once-weekly use in children with GH deficiency (GHD). A phase 2, multinational, randomised, open-label, controlled trial (NCT02616562) investigated the efficacy and safety of somapacitan compared with daily GH (Norditropin®). GH-treatment-naïve prepubertal children with GHD received 0.04 (n = 16), 0.08 (n...

hrp0094p2-450 | Thyroid | ESPE2021

Initial response to thionamide medication in young people with newly diagnosed thyrotoxicosis

Wood Claire , Morrison Niamh , Cole Michael , Donaldson Malcolm , Dunger David , Wood Ruth , Pearce Simon , Cheetham Tim

Methods: Patients commenced 0.75mg/kg carbimazole (CBZ) daily with randomisation to either BR or DT. We examined baseline patient characteristics, CBZ dose, time to serum TSH/FT4 normalisation and BMI Z-score. Results: There were data available from 80 patients (baseline) and 78 patients (61 female) at 6 months. Mean CBZ dose was 0.9 mg/kg/day (BR) and 0.5 mg/kg/day (DT). There was no difference in the time taken for...

hrp0094p2-490 | Thyroid | ESPE2021

Thyroid dyshormonogenesis: a case report of two siblings with a heterozygous variant in the TPO gene.

Vadina Tatiana , Konushova Marina , Eremyan Aikaz , Shreder Ekaterina , Nagaeva Elena , Zaharova Svetlana , Degtyarev Michael , Bezlepkina Olga

Background: Congenital hypothyroidism (CH) is an inborn disease with an incidence rate of 1 case per 3,600 newborns of which 15-20% cases are associated with thyroid dyshormonogenesis. The TPO gene encodes thyroid peroxidase. Disease associated with this gene is usually transmitted in an autosomal recessive mode. Hypothyroidism-associated TPO variants are usually biallelic, limited evidence for cases in patients with heterozygous variants exists.Method...

hrp0094p2-103 | Diabetes and insulin | ESPE2021

Diabetes in a child with infantile onset multisystem neurological, endocrine and pancreatic disease (IMNEPD)

Becker Marianne , Seneca Sara , Schierloh Ulrike , Witsch Michael , de Beaufort Carine , Scalais Emmanuel ,

IMNEPD is a mitochondrial disease caused by homozygous mutations in the PTRH2 gene, a nuclear gene coding for a primary mitochondrial protein. IMNEPD was first described in 2014. So far only 3 other case reports have been published, reporting on a total of 15 patients. We report on two affected siblings of whom the girl developed an antibody negative diabetes at 13 years of age with typical symptoms (polyuria, polydipsia, weight loss of 1,5 kg), and without diabetic k...

hrp0097t19 | Section | ESPE2023

Pre-treatment Blood Transcriptome Predicts Growth Response to Somapacitan Treatment in Children Born Small for Gestational Age

Garner Terence , Clayton Peter , Højby Rasmussen Michael , Murray Philip , Stevens Adam

Treating short stature in children born small for gestational age (SGA) requires daily growth hormone (GH) injections that are burdensome for patients and caregivers. Results from REAL5 (ongoing randomised, multinational, open-label, controlled, dose-finding phase 2 trial; NCT03878446) indicate that somapacitan (0.24 mg/kg/week) has an efficacy, safety, and tolerability profile similar to daily GH (0.067 mg/kg/day) after 52 weeks of treatment in children born SGA. Predicting G...

hrp0097p1-280 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

The Metabolism of 11-Oxy Androgens by Fetal CYP3A7 and CYP3A4 is Less Efficient Compared to Classical Androgens

du Toit Therina , E Flück Christa , V Pandey Amit , Groessl Michael

Steroidogenic enzyme expression in the fetal adrenal and the placenta hints at the production and metabolism of adrenal-derived 11-oxy androgens (11OxyAs) in the fetal-placental unit. Thus, 11OxyAs are present in placental tissue, fetal cord blood and neonatal serum, and could have a particular role during fetal development. The metabolism of the 11OxyAs in the fetal unit, therefore, presents as a focal point of investigation. Adrenal androgens are primarily metabolized by the...

hrp0097p1-320 | Growth and Syndromes | ESPE2023

Achondroplasia: a novel deep intronic variant of the FGFR3 gene, c.1075 + 95C>G, disrupts mRNA splicing

Hogeabri Dorna , Schwarz Stephanie , Oehl-Jaschkowitz Barbara , Gawai Monika , Zemlin Michael , Rohrer Tilman

Background: In the vast majority of cases, achondroplasia and hypochondroplasia are attributable to hotspot missense mutations in the FGFR3 gene. 96% of patients have a G(1138)A and 3% have a G(1138)C point mutation. We report on a family whose members have a deep intronic mutation that leads to a novel cryptic splicing variant of the FGFR3 gene, and via this pathway results in new pathogenicity manifesting as achondroplasia.Case...